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 The mitochondrial-targeted hydrogen sulphide donor, AP39 did not exhibit cytotoxic effects 
in SHSY5Y cells. 
 AP39 generates H2S intracellularly and in co-localisation with the mitochondria. 
 AP39 promotes the cellular bioenergetics in SHSY5Y. 
 AP39 reduces mitochondrial reactive oxygen species. 
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Oxidative stress (OS) resulting from imbalance in the generation of reactive oxygen species (ROS) 
and/or the dysfunction of the antioxidant machinery, is a key mechanism associated with the onset of 
neurodegenerative disorders. Although the molecular mechanisms are still elusive, the onset of 
disorders such as Alzheimer’s and Parkinson’s disease have been associated with mitochondrial 
dysfunction. Recently, a mitochondrial-targeted hydrogen sulphide (H2S) donor, AP39, has shown to 
promote cellular bioenergetics in OS related scenarios. The aim of this study was to explore the 
potential of AP39 to protect the mitochondrial function in an OS environment induced by hydrogen 
peroxide (H2O2). We assessed the potential effects of increasing concentrations of AP39 on cell 
viability, H2S availability and the mitochondrial bioenergetic response in resting (non-differentiated and 
differentiated) neuroblastoma SHSY5Y cell line. Further, we explored the role of AP39 in attenuating 
H2O2-induced mitochondrial dysfunction. Our results showed that nanomolar to micromolar 
concentrations of AP39 (0.1 μM – 3 μM) are not toxic to SHSY5Y cells, regardless of their 
differentiation status. Fluorescence detection of H2S observed AP39 co-localises within the 
mitochondria in a concentration dependent manner. Whilst a lower concentration of AP39 (0.3 μM) 
was required to improve the mitochondrial bioenergetics in resting non-differentiated cells, 1 μM 
produced this effect in their differentiated counterparts. In both, non-differentiated and differentiated 
cells, AP39 reduced H2O2-induced mitochondrial impairments by improving the parameters of the 
mitochondrial function and abrogating the generation of mitochondrial ROS. These suggest that 
mitochondrial targeted delivery of H2S may attenuate neuronal toxicity in neuronal disorders 
associated with OS-induced mitochondrial dysfunction. 
Keywords: Oxidative stress, neurodegenerative disorders, mitochondrial dysfunction, hydrogen 
sulphide donors. 
  






ATP: Adenosine triphosphate. 
AD: Alzheimer’s disease. 
AA: Antimycin. 
FCCP: Carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone.  
H2O2: Hydrogen Peroxide. 
H2S: Hydrogen sulphide. 
MAP-2: Microtubule-associated protein 2. 
mt-ROS: Mitochondrial reactive oxygen species.  
OXPHOS: Oxidative phosphorylation. 
OS: Oxidative stress. 
OCR: Oxygen consumption rates. 
PD: Parkinson’s disease. 
ROS: Reactive oxygen species. 
RA: Retinoic acid. 
Rot: Rotenone. 
SEM: Standard error of mean. 









Neurodegenerative disorders occur due to the progressive and irreversible degeneration of nerve 
cells [1]. These conditions are characterised by the loss of vulnerable neuron populations, leading to 
impaired movement (ataxias) and changes in cognitive functions. Some commonly known 
neurodegenerative disorders include Alzheimer’s disease (AD) and Parkinson’s disease (PD) [1]. AD 
is the most common cause of dementia, mainly affecting people over the age of 65 [2] while PD is a 
neurodegenerative movement disorder associated with selective loss of dopaminergic neurons in the 
substantia nigra of the brain [3]. The pathophysiology of both conditions has been linked to enhanced 
production of reactive oxygen species (ROS) [4,3] and impaired mitochondrial bioenergetics [5,6]. 
Mitochondria are the primary site of energy production within cells [7]. Mitochondrial oxidative 
phosphorylation (OXPHOS) provides energy for neural activity by way of adenosine triphosphate 
(ATP) production [8]. This process continuously produces ROS as a physiological by-product. 
However, dysregulation of cellular antioxidant activity and/or imbalance in ROS production may cause 
oxidative stress (OS) [9]. 
Hydrogen sulphide (H2S) is a gaseous signalling molecule that can stimulate physiological responses 
in various tissues, including the central nervous system [10]. Within optimal concentrations, H2S 
promotes mitochondrial biogenesis and bioenergetics, thereby conferring protection against cellular 
stress [11]. H2S donors show potential therapeutic value against neurodegenerative disorders due to 
their ability to produce anti-oxidant, -inflammatory, and -apoptotic effects in pathological situations. In 
this regard, H2S donors have been shown to reduce cytotoxicity, intracellular protein oxidation, and 
lipid peroxidation in human neuroblastoma cell line SHSY5Y exposed to hypochlorous acid and 4-
hydroxynonenal, which are increased in the temporal and frontal cortex of patients with AD [12,13]. 
Moreover, a rat model of PD, have shown a significant reduction of the endogenous H2S production in 
the substantia nigra of 6-hydroxydopamine (6-OHDA) exposed rats [14] whilst the administration of 
H2S donors have shown to protect against rotenone-induced apoptosis [15] and 6-OHDA-induced 
cytotoxicity [16] by preserving mitochondrial function [10].  
Recently, a mitochondrial-targeted H2S donor, named AP39 was synthesised [17,18]. AP39 has 
shown potential for attenuating mitochondrial-associated OS by exerting cytoprotective effects and 
reducing mitochondrial DNA oxidative damage [17]. Administration of AP39 after cardiopulmonary 
resuscitation showed an improvement in neurological function and survival rate in mice by maintaining 
mitochondrial integrity and reducing ROS [19]. AP39 has also potential for modulating 
neuroinflammation as demonstrated in reducing cytokine release in brains areas affected by 
ischaemia in rats [20].  
The aim of this study was to explore the potential of AP39 to protect neuronal mitochondrial function 
in an OS environment induced by hydrogen peroxide (H2O2). We assessed the effects of increasing 
concentrations of AP39 on cell viability, H2S availability and mitochondrial bioenergetics response in 
resting (non-differentiated and differentiated) neuroblastoma SHSY5Y cell line. Here, we report that 
AP39 targets delivery of H2S to the mitochondria and attenuate H2O2-induced mitochondrial 
dysfunction by improving the parameters of the mitochondrial function and abrogating the generation 
of mitochondrial ROS (mt-ROS). 
Materials and methods: 
Reagents: 
AP39 (Cambridge Biosciences, UK) is a H2S donor consisting of the mitochondria targeting 
triphenylphosphonium (TPP
+
) group ester-linked with the H2S donor ADTOH (5-(4-hydroxyphenyl)-
3H-1,2-dithiole-3-thione) by a ten-carbon alkyl chain (Figure 1). All-trans retinoic acid (RA) and H2O2 
were obtained from Sigma Aldrich (Sigma Aldrich, USA). 
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Cell culture and differentiation  
SHSY5Y neuroblastoma cells were maintained in RPMI 1640 (Gibco, UK) containing 5% FBS and 2 
mM glutamine at 37°C in a humidified atmosphere of 5% CO2. Cells were maintained up to passage 
23. Differentiation to a more mature neuronal-like phenotype (d-SHSY5Y) was ascertained by 
culturing in low FBS (1%) RPMI 1640 supplemented with 10 μM of RA for 6 days. Briefly, cells were 
plated and left to attach overnight (day 0), at day 1, cell culture media was replaced to differentiation 
media (1% FBS and 10 μM RA). Medium was replaced with fresh differentiation media every 48h. 
Differentiation was measured by the extension of long neurites and detected by immunocytochemistry 
using antibodies against microtubule-associated protein 2 (MAP-2) (Sigma Aldrich, USA, catalogue # 
MA512826, 1:100). Cells were grown on glass coverslips (200K cells per coverslip). After 
differentiation, cells were washed in warm PBS and fixed in cooled ethanol for 5 minutes. Coverslips 
were permeabilised in 0.15% triton X-100, blocked in 10% goat serum blocking buffer for 1 h and 
incubated with first antibodies (overnight), followed by Alexa fluor (488) conjugated secondary 
antibodies (Abcam, UK, catalogue # ab175658, 1:500). Coverslips were mounted in glass slides using 
SlowFade™ Diamond Antifade Mountant (Thermo Fisher Scientific, UK). Staining was visualised 
using a Nikon Eclipse Ti-E inverted microscope using 60× objective lens. Images were recorded and 
quantification of immunofluorescence intensity performed in ≥50 cells at day 6, for each differentiation 
treatment. 
Cell treatments with AP39 and H2O2 
SHSY5Y and d-SHSY5Y were exposed to increasing concentrations of AP39 (0.1-10 μM) for 24 h in 
order to assess the effects of AP39 on cell viability. For other experimental protocols either resting 
cells or H2O2-stimulated neuroblastoma cells were exposed to (0.1-1 μM) AP39 for 1h as indicated in 
every figure legend. H2O2 (150-300 μM) was administered for 1 h alone or in combination with AP39 
as indicated in the figure legends. 
Cell viability 
The cytotoxicity profile of AP39 towards SHSY5Y and d-SHSY5Y cells was determined with a 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The MTT is metabolised by viable 
cells to a purple coloured formazan. Briefly, SHSY5Y and d-SHSY5Y were plated at a cell density of 
2.0 x 10
4
 cells/well in 96-well plates and left to attach overnight. After cell attachment, cells were 
exposed to AP39 (0.1-10 μM) for 24 h. Next, cell media was removed and MTT reagent (0.5mg/mL) 
dissolved in RPMI 1640 was added to each well and cells incubated at 37°C in a humidified 
atmosphere of 5% CO2 for 1.5 h. MTT reagent was then aspirated and formazan solubilised in DMSO. 
Absorbance was recorded using a Tecan plate reader at 570nm. 
Determination of intracellular H2S by fluorescence 
H2S availability was evaluated in cells using the specific fluorescent probe Sulphidefluor-7 
acetoxymethyl ester (SF7-AM) (Sigma Aldrich, USA) as previously described [21]. Briefly, cells 
(SHSY5Y and d-SHSY5Y) were plated in 24 well plates at a cell density of 8.0 x 10
4
 cells/well and left 
to attach overnight. Next, cells were exposed to AP39 (0.1-10 μM) for 1 h and then incubated with 2.5 
µM SF7-AM in culture media for 30 min. Cells were washed twice with PBS and the fluorescence was 
measured at 495 nm/519 nm. Images were recorded at 20× using a Nikon Eclipse Ti-E inverted 
microscope. Analysis were performed using Image J. 
Detection of mitochondrial reactive oxygen species (mt-ROS) 
The generation of mt-ROS was ascertained using the fluorescent probe MitoSOX Red (Sigma Aldrich, 
USA) by fluorescent microscopy as previously reported [22]. Briefly, cells (SHSY5Y and d-SHSY5Y) 
were plated on coverslips (2.0 x 10
5
 cells/coverslip) and exposed to H2O2 and AP39 as described on 
the figure legends. Next, coverslips were washed in warm PBS and incubated with MitoSOX Red 
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(5μM) in PBS for 30 min, protected from light. Coverslips were carefully washed with PBS twice and 
fluorescence emitted at 580 nm was recorded and analysed using a Nikon Eclipse Ti-E inverted 
microscope using a 60× objective. 
Cellular bioenergetics 
Parameters of the mitochondrial function were assessed using an XF24 Extracellular Flux Analyser 
(Seahorse Biosciences/Agilent Technologies, UK) following protocols established in our lab 
[22,21,23]. Briefly, SHSY5Y and d-SHSY5Y were plated at 5.0 x 10
4
 cells/well using V7 24 well plates 
(Agilent Technologies, UK) and cells left to attach overnight at 37°C in a humidified atmosphere of 5% 
CO2. Following this, cells were washed and media replaced with non-buffered DMEM (10 mM 
glucose, 1 mM pyruvate and 2 mM L-glutamine) to allow temperature and pH equilibrium. The 
addition of AP39 and/or H2O2 was performed using the available ports of the XF24 Flux Analyser, 
prior to the injections of drugs/inhibitors used to calculate parameters mitochondrial function. Oxygen 
consumption rates (OCR) were measured before and after AP39/ H2O2 injection (first injection), 
followed by sequential injections of oligomycin (1 μM) (Sigma Aldrich, USA), carbonyl cyanide 4-
(trifluoromethoxy) phenylhydrazone (FCCP) (0.5 μM) (Sigma Aldrich, USA) and a mixture of rotenone 
and antimycin A (Rot/AA) (1 μM) (Sigma Aldrich, USA), to inhibit the ATP synthase, uncouple 
oxidative phosphorylation, and estimate non-mitochondrial respiration, respectively (75 μL per 
injection). As previously described [24], injections of these reagents allow parameters of the 
mitochondrial function, including: basal, maximal respiration, spare respiratory capacity, ATP-linked 
OCR and proton leak to be determined. Data was expressed as the rate of oxygen consumption 
(pmolO2/min/μg protein) by time. The concentration of proteins per well was assessed using BCA 
protein assay (Bio-Rad) after the completion of Seahorse assays.  
ATP levels determination 
The ATP Determination Kit (Invitrogen, USA) was used to measure levels of ATP in SHSY5Y and d-
SHSY5Y exposed to AP39. Briefly, cells 5.0 x10
4
 cells/well were plated in 96-well plates, after 
overnight attachment, cells were exposed to AP39 for 1 h. After treatment, cells were processed as 
per manufacturer protocol and luminescence intensity was read using a Tecan microplate reader. 
Readings were expressed as percentage of control. 
Mitochondrial isolation and detection of mitochondrial oxidated proteins 
Isolation of mitochondria was performed using protocols available in our lab [23]. Briefly, SHSY5Y and 
d-SHSY5Y were grown in T125 flasks and exposure to H2O2 and AP39 was as described in the figure 
legend. Following this, mitochondria were isolated by cell disruption followed by differential 
centrifugation. Cells were scrapped in cold PBS and resuspended in mitochondrial isolation buffer (70 
mM sucrose, 210 mM mannitol, 5 mM HEPES, 1 mM, EGTA, pH 7.4). Cells were disrupted and 
homogenised using needle syringe. Homogenates were then centrifuged for 10 min at 11,000 x g, 
4°C. The resulting supernatant was centrifuged for 10 min at 11,000 x g, 4°C and the pellet 
(containing the mitochondria) resuspended in RIPA buffer containing protease inhibitors. Mitochondria 
was disrupted by needle syringe and centrifuged for 10 min at 10,000 x g, 4°C. Finally, the 
supernatant was collected, and protein concentration was measured by BCA protein assay (Bio-Rad). 
A concentration of 10 μg of protein was used to evaluate the protein carbonyl formation, using the 
Protein Carbonyl Content Assay Kit (Abcam, catalogue # ab126287) as previously established in our 
lab and VDAC1 (porin), catalogue # ab34726 was used as the loading control. 
Statistical analysis 
Results are expressed as mean ± standard error of mean (SEM). Statistical analysis was performed 
using GraphPad Prism software (version 8.1.0). A T-test was used to analyse the effects of 
differentiation conditions on MAP-2 expression between two groups (SHSY5Y and d-SHSY5Y) while 
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one-way analysis of variance (ANOVA) was employed to test the differences between more than two 
treatments. Post-hoc comparisons were made using the Tukey’s multiple comparison’s tests. All 
results are expressed as the mean of three independent experiments performed in triplicates. A p < 
0.05 was considered statistically significant.  
Results: 
SHSY5Y differentiation 
The differentiation of neuronal-like cells allows to obtain more mature neuron-like cell populations for 
in vitro testing [25]. To this end, using available protocols established in our lab, SHSY5Y were 
differentiated in low serum media containing RA (10 μM) for 6 days to obtain a more typical neuronal 
morphology [23].  As shown in Figure 2A, at days 0 cells display a characteristic undifferentiated 
phenotype with no particular neurite outgrow. At days 3-6, exposure to RA allowed the formation of 
dendrite-like projections. Successful differentiation was assessed by immunocytochemistry using 
antibodies against the neuronal marker, MAP-2 [26]. Differentiated SHSY5Y (d-SHSY5Y) showed an 
increased expression of MAP-2. By Day 6, the fluorescence intensity of MAP-2 increased 
approximately by 60% in comparison to SHSY5Y (Figure 2B). The differentiation was key for our next 
set of experiments in were we aimed to explore the effects of AP39 and to a non-toxic concentration 
of AP39 that would stimulate the mitochondrial bioenergetics while contrasting potential differences 
between non-differentiated and those displaying a more mature neuronal-like phenotype. 
High concentrations of AP39 reduce SHSY5Y viability 
The cytotoxicity profile of AP39 towards SHSY5Y and d-SHSY5Y cells was assessed with a MTT 
assay to establish suitable concentrations for following experiments. AP39 (0.1-3 μM) showed no 
statistical difference in the reduction of MTT reagent, representative of the viability of the cells. 
However, at 10 μM, AP39 demonstrated a reduction of both SHSY5Y and d-SHSY5Y cells’ viability 
(Figure 3A and 3B, respectively). Based on these observations and previous reports [21,19,27,28], 
we set the following experiments to a range of concentrations of AP39 between 0.1-1 μM. 
AP39 accumulates within the mitochondria and releases H2S 
Once we established a range of AP39 concentrations not detrimental to cell viability, we aimed to 
explore whether these were sufficient to increase the intracellular availability of H2S. Using the 
fluorescent probes; SF7-AM and Mitotracker Red, we observed that in both, SHSY5Y and d-SHSY5Y, 
non-treated cells (controls) displayed SF7-AM fluorescence with no mitochondrial preference. 
However, cells treated with AP39 (0.1-1 μM) induced a concentration-dependent increase in H2S 
generation and these increased signals of SF7AM-H2S detecting probe co-localised within the 
mitochondria (Figure 4A and 4B, SHSY5Y and d-SHSY5Y, respectively). This suggests AP39 
degrades within the mitochondrial compartment of cells to release H2S.  
Effects of AP39 on cellular bioenergetics in resting cells 
The effects of AP39 on cellular bioenergetics was assessed in resting SHSY5Y and d-SHSY5Y 
(Figure 5) cells. We aimed to explore the effects of AP39 on human neuroblastoma cells’ 
bioenergetics and to evidence whether the differentiation of SHSY5Y may have an impact on their 
response to AP39. In SHSY5Y we evidenced that AP39 (0.1-0.3 μM) induced a dose-dependent 
response in parameters of the mitochondrial function as evidenced by increased OCR, that resulted in 
increased basal respiration (p<0.05) vs control (Figure 5A and 5B). However, at 1 μM, a non-
significant increase in OCR, similar to those induced by 0.1 μM was observed, suggesting that AP39 
may have a biphasic effect on non-differentiated human neuroblastoma cells. The OCR-linked to ATP 
production, although not statistically different to control, suggested that AP39 may promote OXPHOS 
and therefore the mitochondrial generation of ATP (Figure 5B). Therefore, we assessed ATP levels 
and observed AP39 (0.3-1 μM) significantly increased ATP generation (p<0.05 and p<0.01 for 0.3 μM 
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and 1 μM AP39 exposed cells, respectively) (Figure 5C). Based on these observations, we 
recognised 0.3 μM as the optimal concentration of AP39 for SHSY5Y that would generate 
mitochondrial-H2S while improving parameters of the mitochondrial function and selected this as the 
concentration to explore in further experiments. 
The differentiation of SHSY5Y cells is accompanied by changes in mitochondrial metabolism and 
antioxidant defences in response to oxidative stress [26]. We aimed to explore whether these would 
impact the response to AP39 in resting conditions. Our experiments using the Seahorse-Agilent XF24 
showed that AP39 (1 μM) significantly improved the basal and maximal respiration in comparison to 
non-treated cells (Figure 5D and 5E). AP39 0.1-0.3 μM showed a dose-dependent response and a 
tendency to improve other parameters of the mitochondrial function such as the maximal respiration 
and ATP-linked OCR. Similar to our observations in SHSY5Y, we evidenced that AP39 improves the 
generation of ATP (Figure 5F). In contrast to our observations in SHSY5Y, we evidenced that for d-
SHSY5Y, the optimum concentration of AP39 to stimulate the cellular bioenergetics was 1 μM. 
Therefore, further experiments using d-SHSY5Y were performed using an AP39 concentration of 1 
μM. 
AP39 improves cellular bioenergetics in cells challenged with H2O2 
Next, we aimed to explore whether AP39 would protect against H2O2 -induced mitochondrial 
impairments and to contrast these effects between SHSY5Y and d-SHSY5Y. To verify our OS model, 
we exposed SHSY5Y to H2O2 for 1h (150-300 μM) and observed H2O2 (300 μM) led to a reduction in 
OCR levels, with significantly reduced basal and maximal respiration linked to a reduced generation 
of ATP (Supplementary figure 1). Then we exposed SHSY5Y and d-SHSY5Y to H2O2 and AP39 an 
evaluated the effects on the mitochondrial bioenergetics. To this end, we injected H2O2, AP39 or 
H2O2/AP39 directly to the wells using the first injection port available in the XF24 instrument. This 
approach allowed to evidence in real-time, the effects on OCR. H2O2 significantly reduced baseline 
OCR levels (p<0.001 vs control and AP39) resulting in reduced basal respiration (p<0.05 vs AP39 
only) (Figure 6A and 6B) and reduced maximal respiration (p<0.05 vs control and AP39 only) (Figure 
6B). However, whilst co-exposure of H2O2 and AP39 resulted in reduced basal respiration, it was 
enough to improve the maximal respiration (Figure 6B).  
Figure 6C and 6D shows the effects of co-exposure of H2O2 and AP39 to d-SHSY5Y. In contrast to 
our observations in SHSY5Y, we evidenced that H2O2 does not significantly reduce the baseline OCR 
and basal respiration in d-SHSY5Y. We only observed a significant impairment of the maximal 
respiration in H2O2-exposed d-SHSY5Y (p<0.05 vs control). The co-administration of H2O2 and AP39 
showed a tendency to improve the basal respiration and maximal respiration to levels similar to non-
treated cells (Figure 6C and 6D).  
AP39 reduces mitochondrial oxidative stress in cells exposed to H2O2 
In order to study the overall mitochondrial oxidative status, we investigated the effects of AP39 in the 
generation of mitochondrial specific reactive oxygen species (mt-ROS) using the fluorescent probe 
MitoSOX Red and analysed mitochondrial protein carbonyls in isolated mitochondria by western blot. 
We analysed the effects of H2O2 on mt-ROS generation in both SHSY5Y and d-SHSY5Y. As shown in 
Figure 7A and 7B, H2O2 (300 μM) increased the MitoSOX Red fluorescence signal. Interestingly, 
H2O2-challenged SHSY5Y showed increased intensity of the signal when contrasted to d-SHSY5Y 
cells also exposed to H2O2. These observations correspond to our observation in Figure 6 where we 
found d-SHSY5Y are less affected by H2O2 exposure. In both, SHSY5Y and d-SHSY5Y, co-
administration of H2O2 with AP39 (0.3 μM for SHSY5Y and 1 μM for d-SHSY5Y, respectively) showed 
a reduction in the MitoSOX fluorescence intensity, suggesting that under OS, AP39 is able to reduce 
the generation of mt-ROS. In line with these findings, SHSY5Y showed higher mitochondrial protein 
carbonyl content when compared to d-SHSY5Y (Figures 7A and 7B, respectively). In SHSY5Y, AP39 
was observed to reduce the mitochondrial protein carbonyl content in comparison to H2O2-treated 
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SHSY5Y (Figure 7A). However, in d-SHSY5Y we evidenced that carbonyl content in AP39 co-treated 
with H2O2 was more evident in some molecular weight bands.  
Discussion: 
OS is a key component in the pathophysiology of several neurological conditions [29,30], including 
neurodegenerative disorders such as Parkinson’s disease [3], and Alzheimer’s disease [31,4]. In this 
study, we explored the potential of AP39, a novel mitochondrial-targeted H2S donor, to protect against 
OS in vitro, contrasting the effects on non-differentiated and differentiated human neuroblastoma cell 
line SHSY5Y exposed to H2O2. Our results suggest a broad range of AP39 concentrations are not 
cytotoxic to SHSY5Y while nanomolar concentrations of AP39 are sufficient to release therapeutic 
levels of H2S in an OS cellular environment, favouring accumulation within the mitochondria. In 
addition, our results demonstrated AP39 was able to promote mitochondrial bioenergetics in both 
SHSY5Y and d-SHSY5Y, however, higher concentrations of AP39 are necessary to promote the 
mitochondrial bioenergetics in d-SHSY5-Y in comparison to their non-differentiated counterparts. 
Linked to these observations, we observed AP39 stimulated the generation of ATP in resting cells. 
Finally, AP39 exerted protective effects in both SHSY5Y and d-SHSY5Y cells exposed to H2O2 by 
supporting the mitochondrial bioenergetics and reducing mitochondrial oxidative status. 
There is an increased interest in the biology of H2S as a large number of scientific reports have 
unravelled many of its downstream physiological effects [30]. H2S not only supports neuronal 
functions but also has been implicated in the improvement of impaired learning and memory [30]. 
Treatments based on inorganic sulphide salts (including NaHS, Na2S, and CaS) have been probed 
as potential treatments to address neurological impairments [32-34]. However, these salts provide 
immediate H2S release which may be unsuitable in the treatment of chronic disease states. 
Furthermore, inorganic sulphide salt administration result in a non-specific delivery of H2S. Exogenous 
H2S is able to impart neuroprotective effects acting as an anti-oxidant, -inflammatory and -apoptotic 
agent [33]. Since these H2S donors deliver H2S not specifically to cellular compartments, a novel 
mitochondrial targeting slow release H2S donor, AP39, consisting of the mitochondria targeting TPP
+
 
group ester-linked with the H2S donor ADTOH was recently developed [18,17]. The TPP
+
 moiety is 
driven by the plasma membrane potential resulting in a fast uptake across the plasma membrane 
[35], resulting in a 500-fold accumulation of linked drugs in mitochondria [36]. In addition, the ADTOH 
moiety is a popular H2S donor observed to exert its pharmacological effects through a concomitant 
increase of both GSH and H2S [37-40] (Figure 1). 
To compare the effects of AP39 on human neuroblastoma cells, we first differentiated SHSY5Y using 
RA protocols. This approach has previously been shown to induce important changes to the cell’s 
phenotype and expression of antioxidant machinery while modulating the response of d-SHSY5Y to 
conditions generating OS [26]. Initially, our approach aimed to verify the appropriate concentration of 
AP39 that would be non-toxic to cells while improve the mitochondrial bioenergetics. We observed 
that the condition of differentiation did not alter the cell viability of human neuroblastoma cells to 
increasing concentrations of AP39 as assessed by MTT assay. Reports by Gero et al 2016, showed 
that sub-micromolar concentrations of AP39 are safe to use on endothelial cells [18], while our report 
suggest that human neuroblastoma cells are slightly more resistant to AP39 toxicity as we evidenced 
tolerability in a micromolar range. Interestingly, H2S generation from AP39 occurs through multiple 
steps each of which are affected by various metabolites in the mitochondria [18]. Further, it has been 
suggested that the H2S concentration within mitochondria remains below the toxic limit since 
normalisation of the mitochondrial potential will reduce drug accumulation [36], suggesting that an 
even at 10 μM, AP39 may not necessarily cause toxicity due to insufficient drug accumulation in 
mitochondria.  
The role of mitochondrial dysfunction in the onset of neurological disorders has been linked to the 
increased oxygen demand, susceptibility to peroxidation of lipids and imbalance in antioxidant 
mechanisms [41]. In this regard, the genesis of PD has been implicated at the genetic and 
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environmental levels [42,43]. As described, AP39 has shown potential for protecting the mitochondrial 
function and mt-ROS generation by the targeted delivery of H2S. Our observations evidenced that for 
both, SHSY5Y and d-SHSY5Y, sub-micromolar levels of AP39 caused accumulation of H2S in the 
mitochondria. However, we observed that d-SHSY5Y required a greater concentration of AP39 to 
significantly improve mitochondrial bioenergetics. Previously, it has been demonstrated that the 
differentiation of SHSY5Y leads to reduced mitochondrial membrane potential observed as an 
approximately 200% reduction in mitochondrial TMRM fluorescent probe intensity [44]. Consistent 
with these observations, we infer that higher concentrations of AP39, perhaps required to normalise 
the mitochondrial membrane potential, are necessary to exert its effects on the mitochondrial function. 
Following this rationale, to exert a similar effect in SHSY5Y, less AP39 might be required, resulting in 
a different response to AP39 in regards to the SHSY5Y differentiation status. However, more analysis 
and quantification of mitochondrial to cytoplasmic levels of H2S might be necessary to support this 
hypothesis. 
ROS are emerging as key signalling molecules participating in a myriad of physiological functions 
[45]. Increased generation and accumulation of ROS, in particular at the mitochondrial level, may 
result in mitochondrial OS leading to a range of cellular concerns including inflammation and death 
[9]. The modulation of oxidative damage to the mitochondria may be a novel strategy to address OS-
related neuronal disorders with AP39 demonstrating potential to reduce intracellular oxidant 
production, both in vitro and in vivo. Interestingly and in contrast to other research groups exploring 
the potential for AP39 to protect the neuronal functions we observed that human derived cells may 
have a different behaviour in response to AP39. As we stated before, a range of concentrations of 
AP39 up to 1 μM may produce beneficial effects against OS. However, other authors exploring mice-
derived neurons have shown that up to 0.1 μM AP39 is sufficient to stimulate the cellular 
bioenergetics while concentrations of 0.250 μM resulted in a inhibition of the cellular bioenergetics 
[27]. These striking differences in terms of AP39 concentration suggest that human cells types may 
respond differently to other organisms’ cells and stress the importance of exploring the effects of 
novel molecules using efficient human models. Moreover, similar to previous reports [26], our results 
regarding d-SHSY5Y, displayed a somewhat OS-resistant phenotype (Figures 6 and 7). These 
effects may be attributed to the variation in the expression of mitochondrial protein levels [26].  
Consequently, these observations suggest that a mature neuronal-like cells may better resemble and 
test the response to H2S-inhibitory effects. However, the exact molecular mechanisms implicated in 
these observations remain to be investigated in further experiments. 
Conclusions 
As far as we are aware, our results provide novel evidence of the potential of AP39 in human 
neuronal-like cells for the modulation of mitochondrial related-OS and describe the contrasting effects 
of AP39 on non-differentiated and differentiated human neuroblastoma cells SHSY5Y. These 
observations suggest that nanomolar to micromolar concentrations of AP39 may be sufficient to exert 
beneficial effects on the neuronal bioenergetics, including the modulation of the mitochondrial 
bioenergetics and ROS generation. As neurological disorders are associated with increased OS and 
defective mitochondria, our results suggest that H2S-related compounds, in particular AP39, may offer 
new therapeutic opportunities that warrant further exploration. 
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Figure 1. Chemical Structures depicting ADTOH (5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione), TPP
+ 
(triphenylphosphonium) and AP39 (TPP
+ 
linked to ADTOH). 
 
Figure 2. Differentiation of neuronal SHSY5Y cell line using retinoic acid (RA) in low FBS 
environment. (A) Bright field images depicting SHSY5Y differentiation with 10 μM RA and 1% FBS. 
Neurite extension was effective after 6 days (arrows). (B) Immunocytochemistry against MAP-2 
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(green) and DAPI (blue). Quantification was performed with ≥ 50 cells for each differentiation 
treatment at day 6. Data= mean ± SEM. ****p<0.0001 vs non-differentiated SHSY5Y.  
 
Figure 3. Effect of AP39 on SHSY5Y and d-SHSY5Y cell viability. (A) SHSY5Y and (B) d-SHSY5Y 
we exposed to 0.1-10 μM AP39 for 24 h and cell viability ascertain by MTT assay. Data= mean ± 
SEM. **p<0.01 vs control (no AP39). 




Figure 4. AP39 generates intracellular H2S. (A) SHSY5Y and (B) d-SHSY5Y were exposed to various 
concentrations of AP39 for 1 h and intracellular H2S was detected using Sf7-AM fluorescent probe 
and mitochondrial localization was monitored by MitoTracker Red as described in Materials and 
Methods. 




Figure 5. Effect of AP39 on resting non-differentiated and differentiated SHSY5Y mitochondrial 
bioenergetics exposed to increasing concentrations of AP39. (A-C) oxygen consumption expressed 
by time, their calculated mitochondrial bioenergetics parameters and ATP levels in SHSY5Y and (D-
F) d-SHSY5Y. H/V: H2O2 (300 μM) and/or vehicle. O: Oligomycin. F: FCCP. R/A: mixture of antimycin 
A and rotenone. Data= mean ± SEM. *p<0.05, **p<0.01 vs control (no AP39). $ p<0.05 vs AP39. 




Figure 6. AP39 improve the mitochondrial respiration in H2O2-exposed neuroblastoma cells. Oxygen 
consumption traces expressed by time and their calculated mitochondrial bioenergetics parameters in 
non-differentiated (A-B) and differentiated (C-D) SHSY5Y cells. H/V: H2O2 (300 μM) and/or vehicle. O: 
Oligomycin. F: FCCP. R/A: mixture of antimycin A and rotenone. Data= mean ± SEM. *p<0.05, 
**p<0.01, ***p<0.001 vs control (no AP39). $ p<0.05 vs AP39. 




Figure 7. AP39 ameliorates H2O2-induced mt-ROS generation. The generation of mitochondrial 
specific ROS was detected by fluorescence microscopy using the fluorescent probe MitoSOX Red 
using 60X magnification. Protein carbonyl content was detected in isolated mitochondria by western 
blot in (A) SHSY5Y and (B) d-SHSY5Y. VDAC1 (porin) was used as mitochondrial protein loading 
control. A: Control. B: H2O2. C: AP39. D: H2O2 + AP39. 
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